Huffpost Business

Drug Improves Survival Rate Of Late-Stage Lung Cancer Patients

Posted: Updated:

ImClone Systems Inc. and Bristol-Myers Squibb Co. said Tuesday the drug Erbitux improved the survival rate of lung cancer patients in a late-stage study.

The drug, already approved to treat colon cancer and head and neck cancer, was given to patients with advanced non-small cell lung cancer in combination with chemotherapy treatment including vinorelbine and cisplatin. The study compared the combination to chemotherapy alone.

Read the whole story at CNNMoney